Press release
Currently, 130+ Key Companies are Actively Developing Therapies for the Treatment of Soft Tissue Sarcoma
Soft Tissue Sarcoma Pipeline
The report provides a detailed description of the drug, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any).
The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.
Soft Tissue Sarcoma Pipeline Analysis
The report provides insights into:
The report provides detailed insights about companies that are developing therapies in the Soft Tissue Sarcoma Market.
It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Soft Tissue Sarcoma Treatment.
Soft Tissue Sarcoma key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Soft Tissue Sarcoma Drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Soft Tissue Sarcoma market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Request for Sample PDF: https://www.delveinsight.com/sample-request/soft-tissue-sarcoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Soft Tissue Sarcoma Therapeutics Analysis
Currently, more than 130+ key companies are developing therapies for Soft Tissue Sarcoma. The companies which have their Soft Tissue Sarcoma drug candidates in the most advanced stage, i.e., phase III, include, Philogen.
Some of the key companies in the Soft Tissue Sarcoma Market include Advenchen Laboratories, Philogen, Gradalis, Epizyme, Eli Lilly and Company, Chugai Pharma France, CytRx, AROG Pharmaceutical, Taiho Pharmaceuticals, NantCell, KaryoPharm Therapeutics, Nanobiotix, Apexigen, Gem Pharmaceuticals, Lytix Biopharma, Novartis, Athenex, Bristol Myers Squibb, Merck Sharp & Dohme, Bristol Myers Squibb, Incyte Corporation, Daiichi Sankyo, AstraZeneca, Pfizer, Merck Sharp & Dohme, NantPharma, Iovance Biotherapeutics, Agenus, Eli Lilly and company, AstraZeneca, Adaptimmune, Aadi, Jiangsu HengRui Medicine, Bayer, Merck, GlaxoSmithKline, AVEO Pharmaceuticals, Amgen, Atara Biotherapeutics, Roche, Bayer, VasGene Therapeutics, Mirati Therapeutics, EMD Serono, AGC Biologics, Novartis, Genor Biopharma, Clovis Oncology, PharmaMar, Boehringer Ingelheim, Morphotek (Eisai), GlaxoSmithKline, Novartis, Incyte Corporation, Tracon Pharmaceuticals, Jiangsu Hengrui Medicine, Exelixis, Sanofi, Pfizer, Merck KGaA, Roche Pharma AG, Bristol-Myers Squibb, Bristol-Myers Squibb, MedImmune, Qbiotics, AstraZeneca, Novartis, AstraZeneca, Aadi, Loxo Oncology, and many others.
Soft Tissue Sarcoma Therapies covered in the report include:
AL3818 (Advenchen Laboratories)
L19 TNF (Philogen)
NBTXR3 (Nanobiotix)
GPX-150 (Monopar Therapeutics)
LTX-315 (Lytix Biopharma)
Nivolumab (Bristol Myers Squibb)
Lenvatinib (Merck sharp & Dohme Corp.)
Durvalumab (AstraZeneca)
Nintedanib (Boehringer Ingelheim)
And many more
Request the Sample PDF to Get a more in-depth Assessment:
https://www.delveinsight.com/report-store/soft-tissue-sarcoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Table of Content
1. Report Introduction
2. Executive Summary
3. Soft Tissue Sarcoma Current Treatment Patterns
4. Soft Tissue Sarcoma - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Soft Tissue Sarcoma Late Stage Products (Phase-III)
7. Soft Tissue Sarcoma Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Soft Tissue Sarcoma Discontinued Products
13. Soft Tissue Sarcoma Product Profiles
14. Soft Tissue Sarcoma Key Companies
15. Soft Tissue Sarcoma Key Products
16. Dormant and Discontinued Products
17. Soft Tissue Sarcoma Unmet Needs
18. Soft Tissue Sarcoma Future Perspectives
19. Soft Tissue Sarcoma Analyst Review
20. Appendix
21. Report Methodology
*The table of contents is not exhaustive; the final content may vary.
Request for the Sample PDF (to get a detailed understanding of the TOC, Tables, and Figures included in the report), at: https://www.delveinsight.com/report-store/soft-tissue-sarcoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Contact Info:
Anuj Rawat
Email: info@delveinsight.com
https://www.delveinsight.com/
Request for Sample Copy of the Report at:
https://www.delveinsight.com/sample-request/soft-tissue-sarcoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Currently, 130+ Key Companies are Actively Developing Therapies for the Treatment of Soft Tissue Sarcoma here
News-ID: 2682950 • Views: …
More Releases from DelveInsight Business Research
Primary Biliary Cholangitis Market Expected to Experience Major Growth by 2034, …
DelveInsight's "Primary Biliary Cholangitis Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Primary Biliary Cholangitis, historical and forecasted epidemiology as well as the Primary Biliary Cholangitis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Primary Biliary Cholangitis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Primary Biliary Cholangitis…
Advanced Renal Cell Carcinoma Pipeline 2025: Therapies, MOA Insights, and Key Cl …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Advanced Renal Cell Carcinoma pipeline constitutes 50+ key companies continuously working towards developing 60+ Advanced Renal Cell Carcinoma treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Advanced Renal Cell Carcinoma Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across…
Alport Syndrome Market Forecasted to Surge in Coming Years, 2024-2034 Analysis b …
DelveInsight's "Alport Syndrome Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Alport Syndrome, historical and forecasted epidemiology as well as the Alport Syndrome market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Alport Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Alport Syndrome Market Forecast
https://www.delveinsight.com/sample-request/alport-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the…
Angioedema Pipeline 2025: FDA Approvals and Clinical Trials Landscape with MOA a …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Angioedema pipeline constitutes 20+ key companies continuously working towards developing 20+ Angioedema treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The Angioedema Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed…
More Releases for Soft
Soft Robotic Gripper Market Size, Trends Analysis 2033 by Key Vendors- SoftGripp …
USA, New Jersey: According to Verified Market Reports analysis, the global Soft Robotic Gripper Market sizewas valued at USD 1.2 Billion in 2024 and is estimated to reach USD 5.7 Billion by 2033, growing at a CAGR of 18.6% from 2026 to 2033.
How AI and Machine Learning Are Redefining the Future of the Soft Robotic Gripper Market?
AI and machine learning are accelerating a new era of intelligent automation, enabling soft…
Robot Soft Gripper Market
Robot Soft Gripper Market size is estimated to be USD 1.2 Billion in 2024 and is expected to reach USD 3.5 Billion by 2033 at a CAGR of 15.6% from 2026 to 2033.
What are the potential factors contributing to the growth of the robot soft gripper market?
The growth of the robot soft gripper market is driven by several key factors. Increasing adoption of automation across various industries such as electronics,…
Soft Drink Concentrates Market
Introduction
The soft drink concentrates market plays a pivotal role in the global beverage industry. These concentrates are primarily used to prepare soft drinks, offering a cost-effective and efficient way for manufacturers to produce various beverages. Soft drink concentrates are essentially flavored syrups or powders that, when mixed with water or carbonated water, create popular soft drinks. The market for these concentrates has seen remarkable growth in recent years, driven by…
Soft Robot Technology Market Upcoming Trend & Positions 2027 | Cyberdyne, Soft R …
Soft Robot Technology Market Strengths, Weaknesses, Opportunities, and Threats analysis.
Demanding Market Research Report on Global Soft Robot Technology Market conducted by a team of industry specialists. The report covers briefly the products or services in the market and their application. The report also provides data on the technological advancements taking place in the Soft Robot Technology market, helping the market vendors to increase their business productivity and operational efficiency. The…
Soft Skills Management Market - Increasing Demand For Cloud-Based Soft Skill Tra …
According to a new market report published by Transparency Market Research, the global soft skills management market was valued at US$ 11,289.7 Mn in 2016 and is expected to expand at a CAGR of 11.9% from 2018 to 2026, reaching US$ 33,736.1 Mn by the end of the forecast period. According to the report, the global soft skills management market will continue to be influenced by a range of macroeconomic…
Suma Soft
Texas (USA), Canada (Toronto) & India (Business Network)— Suma Soft’s BPO for companies in USA, Canada and UK efficiently streamline business processes. Suma Soft has developed an integrated back-office system that assists these companies giving them round the clock support.
Credibility & Certification :
Suma Soft is an ISO 27001 and 9001 certified company which gives paramount importance to security, accuracy and quality while delivering BPO support services. We have a…
